annamycin

Oncology A liposomal anthracycline for treating CAs–eg multiple-drug-resistant tumors–eg, refractory breast CA, refractory/relapsed AML, ALL, blast crisis of CML. See Anthracycline, Liposomes.

References in periodicals archive ?

L- Annamycin, a member of the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including potential activity against multi- drug resistant tumors and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives.

Callisto Pharmaceuticals Completes Enrollment of Phase II Trial of Atiprimod in Neuroendocrine Cancer

Callisto initiated a clinical trial of L- Annamycin in adult relapsed or refractory acute lymphoblastic leukemia patients in 4Q 2005.

Callisto Pharmaceuticals Opens Additional Site for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients

L- Annamycin, a new compound from the anthracycline family of proven anti-cancer drugs, has a novel therapeutic profile, including activity against resistant diseases and significantly reduced cardiotoxicity, or damage to the heart, compared to currently available drug alternatives.

Callisto Pharmaceuticals, Inc. Receives Notice From AMEX

Callisto has been conducting a well-controlled study using single-agent L- Annamycin in the treatment of adults with relapsed or refractory acute ALL to confirm the maximum tolerated dose (MTD) reported from the previous sponsor.

Callisto Reports on 2006 and First-Quarter 2007 Clinical and Corporate Milestones and Achievements

Callisto initiated a clinical trial of L- Annamycin in pediatric acute leukemia patients in 1Q 2007 and initiated a trial in adult relapsed or refractory acute lymphoblastic leukemia patients in 4Q 2005.

Callisto Pharmaceuticals Announces Publication of Research Article on Atiprimod Preclinical Studies in Mantle Cell Lymphoma

Full browser ?

CITE

Site: Follow: Share:

Open / Close